Protein Kinases and Parkinson’s Disease
AbstractCurrently, the lack of new drug candidates for the treatment of major neurological disorders such as Parkinson’s disease has intensified the search for drugs that can be repurposed or repositioned for such treatment. Typically, the search focuses on drugs that have been approved and are used clinically for other indications. Kinase inhibitors represent a family of popular molecules for the treatment and prevention of various cancers, and have emerged as strong candidates for such repurposing because numerous serine/threonine and tyrosine kinases have been implicated in the pathobiology of Parkinson’s disease. This review focuses on various kinase-dependent pathways associated with the expression of Parkinson’s disease pathology, and evaluates how inhibitors of these pathways might play a major role as effective therapeutic molecules. View Full-Text
Share & Cite This Article
Mehdi, S.J.; Rosas-Hernandez, H.; Cuevas, E.; Lantz, S.M.; Barger, S.W.; Sarkar, S.; Paule, M.G.; Ali, S.F.; Imam, S.Z. Protein Kinases and Parkinson’s Disease. Int. J. Mol. Sci. 2016, 17, 1585.
Mehdi SJ, Rosas-Hernandez H, Cuevas E, Lantz SM, Barger SW, Sarkar S, Paule MG, Ali SF, Imam SZ. Protein Kinases and Parkinson’s Disease. International Journal of Molecular Sciences. 2016; 17(9):1585.Chicago/Turabian Style
Mehdi, Syed J.; Rosas-Hernandez, Hector; Cuevas, Elvis; Lantz, Susan M.; Barger, Steven W.; Sarkar, Sumit; Paule, Merle G.; Ali, Syed F.; Imam, Syed Z. 2016. "Protein Kinases and Parkinson’s Disease." Int. J. Mol. Sci. 17, no. 9: 1585.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.